Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03611153 · ClinicalTrials.gov registry record · Phase 1
Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03611153: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03611153 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03611153, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
Interventions
- DRUG Placebo oral capsule
- DRUG AZD4831 Oral Myeloperoxidase Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2022-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03611153
The ClinicalTrials.gov registry entry for NCT03611153 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03611153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03611153 about?
NCT03611153 is a clinical study titled "Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)". Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
What is the current status of trial NCT03611153?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-07-01. Estimated completion is 2022-02-24.
What interventions are being tested in trial NCT03611153?
The interventions under investigation include: Placebo oral capsule (DRUG), AZD4831 Oral Myeloperoxidase Inhibitor (DRUG).
Who is sponsoring clinical trial NCT03611153?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.